Cardiopulmonary manifestations of progressive systemic sclerosis: associations with circulating immune complexes and fluorescent antinuclear antibodies. 1979

E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger

Sixteen patients with progressive systemic sclerosis were evaluated for cardiopulmonary manifestations of their disease and for serologic immune abnormalities. Twenty-five percent of patients had abnormal echocardiograms, and 81% had a significant reduction in pulmonary function by spirometry. Circulating immune complexes (IC) were detected in 44% of patients by using a fluorescent Raji cell assay, and these patients were more likely to have an abnormal echocardiogram (P less than 0.02). Seventy-five percent of the patients had fluorescent antinuclear antibodies (FANA) and these patients were more likely to have pulmonary disease (P less than 0.01).

UI MeSH Term Description Entries
D008450 Maximal Midexpiratory Flow Rate Measurement of rate of airflow over the middle half of a FORCED VITAL CAPACITY determination (from the 25 percent level to the 75 percent level). Common abbreviations are MMFR and FEF 25%-75%. Forced Expiratory Flow 025-075 Percent,FEF 25-75 Percent,Flow Rate, Maximal Midexpiratory,MMFR,25-75 Percent, FEF,25-75 Percents, FEF,FEF 25 75 Percent,FEF 25-75 Percents,Forced Expiratory Flow 025 075 Percent,Percent, FEF 25-75,Percents, FEF 25-75
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012119 Respiration The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration ( Breathing
D004452 Echocardiography Ultrasonic recording of the size, motion, and composition of the heart and surrounding tissues. The standard approach is transthoracic. Echocardiography, Contrast,Echocardiography, Cross-Sectional,Echocardiography, M-Mode,Echocardiography, Transthoracic,Echocardiography, Two-Dimensional,Transthoracic Echocardiography,2-D Echocardiography,2D Echocardiography,Contrast Echocardiography,Cross-Sectional Echocardiography,Echocardiography, 2-D,Echocardiography, 2D,M-Mode Echocardiography,Two-Dimensional Echocardiography,2 D Echocardiography,Cross Sectional Echocardiography,Echocardiography, 2 D,Echocardiography, Cross Sectional,Echocardiography, M Mode,Echocardiography, Two Dimensional,M Mode Echocardiography,Two Dimensional Echocardiography
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000936 Antigen-Antibody Complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES. Immune Complex,Antigen-Antibody Complexes,Immune Complexes,Antigen Antibody Complex,Antigen Antibody Complexes,Complex, Antigen-Antibody,Complex, Immune,Complexes, Antigen-Antibody,Complexes, Immune
D000974 Antibodies, Antinuclear Autoantibodies directed against various nuclear antigens including DNA, RNA, histones, acidic nuclear proteins, or complexes of these molecular elements. Antinuclear antibodies are found in systemic autoimmune diseases including systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, and mixed connective tissue disease. Anti-DNA Antibodies,Antibodies, Anti-DNA,Antinuclear Antibodies,Antinuclear Autoantibodies,Antinuclear Autoantibody,Antinuclear Factors,Antinuclear Antibody,Antinuclear Factor,Anti DNA Antibodies,Antibody, Antinuclear,Autoantibody, Antinuclear,Factor, Antinuclear

Related Publications

E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
October 1982, Arthritis and rheumatism,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
January 1985, Clinical and experimental rheumatology,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
August 1986, Revista medica de Chile,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
September 1980, The Indian journal of medical research,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
May 1985, Revista medica de Chile,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
October 1968, Arthritis and rheumatism,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
November 1991, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
February 1984, Minerva medica,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
July 1981, Alergia,
E Pisko, and K Gallup, and R Turner, and M Parker, and A M Nomeir, and J Box, and J Davis, and P Box, and H Rothberger
April 1982, Clinical and experimental immunology,
Copied contents to your clipboard!